Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review
Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, Risk M, Rwabasonga B, Wilt TJ
Record ID 32016000833
English
Authors' objectives:
To assess the efficacy, comparative effectiveness, and adverse effects of newer drugs to treat lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH).
Authors' recommendations:
Several drugs newly used for LUTS attributed to BPH, alone or in combination with older AB, showed evidence of efficacy in short-term studies; however, comparative effectiveness for silodosin, fesoterodine/AB combination, and tadalafil showed that outcomes were similar to older AB monotherapy and adverse effects were often higher with the newly used drugs or combination therapies. Evidence on long-term efficacy and adverse effects was insufficient.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
https://www.effectivehealthcare.ahrq.gov/ehc/products/605/2235/prostatic-hyperplasia-medications-report-160524.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Lower Urinary Tract Symptoms
- Male
- Prostatic Hyperplasia
- Risk Factors
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.